JNJ Wins Second FDA Approval in Two Months for Rare Disease Treatment

Johnson & Johnson (JNJ) has received another approval from the US Food and Drug Administration (FDA). The regulator approved JNJ's drug Imaavy to treat patients 12 years old and above with a rare life-threatening condition called warm autoimmune hemolytic anemia (wAIHA).

wAIHA is a condition where autoantibodies attack red blood cells, causing severe anemia and fatigue. According to JNJ, between one and three new people per 100,000 are affected by wAIHA each year.

This FDA approval marks the second win for JNJ in as many months. In July, the company won approval for its dual-energy ablation catheter, which can deliver radiofrequency and pulsed field energy to treat atrial fibrillation, a common heart rhythm disorder.

JNJ's share price has risen significantly over the past year, increasing by 51% over the past 52 weeks. This outperforms the broader market, which is up around 19% over that time period, as measured by the S&P 500 index.